Cocrystal Pharma, Inc. - Form 8-K Summary
Business Context and Reporting Period
This Current Report on Form 8-K was filed by Cocrystal Pharma, Inc. on January 18, 2018, reporting events occurring on that date. The Company is incorporated in Delaware and maintains its principal executive offices in Tucker, Georgia.
Key Financial Metrics
The filing text does not provide a clear value for revenue, profit, cash flow, margins, debt, or liquidity. This report focuses exclusively on corporate governance and capital structure changes rather than operational financial performance.
Material Changes
- Reverse Stock Split: The Board of Directors approved a one-for-30 reverse split of the Company's Common Stock.
- Effective Date: The amendment to the Certificate of Incorporation was filed on January 18, 2018, and the split took effect on January 24, 2018.
- Fractional Shares: No fractional shares will be issued. Shareholders entitled to fractional shares will receive cash payments in lieu thereof.
- Par Value: There was no change in the par value of the common stock.
Guidance, Outlook, and Risks
The filing text does not provide a clear value for future guidance, management outlook, specific risks, or contingencies beyond the execution of the stock split. The report notes that the description of the amendment is qualified by the full text of the Certificate of Amendment attached as Exhibit 3.1.
Key Facts for Investor Verification
- Verify the post-split share count and trading symbol status on the effective date of January 24, 2018.
- Confirm the cash payment process for shareholders holding fractional shares.
- Review the attached Exhibit 3.1 (Certificate of Amendment) for the complete legal terms of the reverse split.
- Check subsequent filings for any impact on the Company's compliance with exchange listing requirements.